Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Nov;103(5):453-459.
doi: 10.1111/ejh.13291. Epub 2019 Sep 5.

Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort study

Claire van de Ree-Pellikaan  1 , Arne de Kreuk  2 , Cees G Schaar  3 , Aart Beeker  4 , Ellen C Dompeling  5 , Cees J H Gerrits  6 , Anja A van Houten  7 , Martin R Schipperus  8 , Leonie Strobbe  9 , Eduardus F M Posthuma  10 , Karin Klauke  11 , Peter E Westerweel  1
Affiliations
Clinical Trial

Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort study

Claire van de Ree-Pellikaan et al. Eur J Haematol. 2019 Nov.

Abstract

Objectives: Assessment of "real-world" treatment strategies and outcome in Dutch polycythemia vera (PV) patients.

Methods: Retrospective chart review in 150 patients with PV (WHO 2008 diagnostic criteria) from 10 major non-academic hospitals in the Netherlands.

Results: Patients (median age 64 years, 49% male) frequently had cardiovascular risk factors (56%) and prior vascular events (31%). About 70% of patients were high-risk, based on ELN criteria. However, the majority of patients were treated with phlebotomies alone (55%). Cytoreduction with hydroxyurea (HU) was received by 44% as part of their initial therapy, with or without phlebotomies. The time to achieve the 45% hematocrit target was shortest in patients treated with phlebotomies with or without HU (125 ± 99 and 197 ± 249 days, respectively) compared to patients treated with only HU (232 ± 216 days). Leukocyte and platelet levels were lower in HU-treated patients, and ELN response targets were more often reached. During the median follow-up period of 4.1 years, 14 patients (9%) suffered a thrombotic vascular event.

Conclusions: In Dutch clinical practice, there is major clinical variation in treatment strategies for PV. Phlebotomizing patients shorten the time to achieve hematocrit control, while HU better controls platelet and leukocyte levels. The thrombotic vascular event rate remains clinically significant.

Keywords: cytoreduction; hydroxyurea; phlebotomy; polycythemia vera; real-world data.

PubMed Disclaimer

References

REFERENCES

    1. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595-600.
    1. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289-297.
    1. Passamonti F. How I treat polycythemia vera. Blood. 2012;120:275-284.
    1. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
    1. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22-33.

Grants and funding

LinkOut - more resources